NASDAQ:SCTX

Scribe Therapeutics Q3 2026 Earnings Results & Report

Scribe Therapeutics logo
$13.13 -0.92 (-6.55%)
As of 02:25 PM Eastern

Scribe Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.68 versus the -$0.42 consensus estimate, while revenue was $1.64 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Scribe Therapeutics EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.42
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A

Scribe Therapeutics Revenue Results

Actual Revenue
$1.64 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scribe Therapeutics Q3 2026 Earnings FAQ

Scribe Therapeutics (NASDAQ:SCTX) reported earnings of -$0.68 per share for Q3 2026, missing the consensus estimate of -$0.42. The report was announced on Thursday, November 12, 2026.

Scribe Therapeutics reported revenue of $1.64 million for Q3 2026.

Scribe Therapeutics Earnings Headlines

A Bill Would Reprice America's Gold at Market Value
The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel
See More Scribe Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scribe Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scribe Therapeutics and other key companies, straight to your email.

About Scribe Therapeutics

Scribe Therapeutics (NASDAQ:SCTX) is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas.

Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.

View Scribe Therapeutics Profile